Physician profile
Peter Pimpinelli
NPI 1871903880
$3,209.21
in general payments reported to CMS, 2019-2025
22 companies · $2,121 in 2025
The $2,121 reported for 2025 was more than what 93% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $90.09 · 2022: $194 · 2023: $570 · 2024: $235 · 2025: $2,121.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,591 · Food and Beverage: $1,334.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,591.05 |
| Food and Beverage | $1,334.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tandem Diabetes Care, INC. | $1,776.06 | 2021-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Medtronic, INC. | $333.92 | 2021-2025 | Minimed 780g, Inpen Smart Insulin Delivery System |
| Novo Nordisk INC | $177.44 | 2023-2025 | Sogroya |
| Ascendis Pharma Endocrinology INC | $168.42 | 2022-2023 | |
| Pfizer INC. | $150.17 | 2023-2025 | |
| Abbvie INC. | $128.73 | 2023-2024 | |
| Insulet Corporation | $75.74 | 2022-2025 | Omnipod |
| Dexcom, INC. | $55.99 | 2022-2023 | Dexcom G6 Transmitter |
| Tolmar, INC. | $45.85 | 2023-2024 | |
| Abbott Laboratories | $44.70 | 2022-2025 | Freestyle Libre |
| Sanofi-Aventis U.S. LLC | $35.39 | 2024-2025 | |
| Neurocrine Biosciences, INC. | $34.66 | 2025 | |
| Tolmar Pharmaceuticals, INC. | $26.63 | 2021-2022 | |
| Soleno Therapeutics, INC. | $25.21 | 2025 | Vykat Xr |
| Alexion Pharmaceuticals, INC. | $21.12 | 2025 | Strensiq |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sequel Med Tech, LLC | $18.57 | 2025 | Twiist |
| Sanofi Pasteur INC. | $17.00 | 2023 | |
| Edwards Lifesciences Corporation | $16.88 | 2025 | Sapien 3 Ultra Resilia |
| Eton Pharmaceuticals, INC. | $15.97 | 2021 | |
| Azurity Pharmaceuticals, INC. | $14.54 | 2023 | Triptodur |
| Xeris Pharmaceuticals, INC. | $13.39 | 2021 | |
| Cranial Technologies, INC | $12.83 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Pimpinelli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.